Directed evolution of a recombinase that excises the provirus of most HIV-1 
primary isolates with high specificity.

Karpinski, Janet; Hauber, Ilona; Chemnitz, Jan; Schäfer, Carola; Paszkowski-Rogacz, Maciej; Chakraborty, Debojyoti; Beschorner, Niklas; Hofmann-Sieber, Helga; Lange, Ulrike C; Grundhoff, Adam; Hackmann, Karl; Schrock, Evelin; Abi-Ghanem, Josephine; Pisabarro, Maria Teresa; Surendranath, Vineeth; Schambach, Axel; Lindner, Christoph; Lunzen, Jan van; Hauber, Joachim; Buchholz, Frank

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.

MPS-Authors

Schrock, Evelin
Max Planck Society;

Pisabarro, Maria Teresa
Max Planck Society;

Lindner, Christoph
Max Planck Society;

/persons/resource/persons219042

Buchholz, Frank
Max Planck Institute of Molecular Cell Biology and Genetics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Karpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski-Rogacz, M., Chakraborty, D., et al. (2016). Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nature biotechnology, 34(4), 401-409.

Cite as: https://hdl.handle.net/21.11116/0000-0001-02C1-2

Abstract

Current combination antiretroviral therapies (cART) efficiently suppress HIV-1 reproduction in humans, but the virus persists as integrated proviral reservoirs in small numbers of cells. To generate an antiviral agent capable of eradicating the provirus from infected cells, we employed 145 cycles of substrate-linked directed evolution to evolve a recombinase (Brec1) that site-specifically recognizes a 34-bp sequence present in the long terminal repeats (LTRs) of the majority of the clinically relevant HIV-1 strains and subtypes. Brec1 efficiently, precisely and safely removes the integrated provirus from infected cells and is efficacious on clinical HIV-1 isolates in vitro and in vivo, including in mice humanized with patient-derived cells. Our data suggest that Brec1 has potential for clinical application as a curative HIV-1 therapy.